Stay updated on Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page.

Latest updates to the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe displayed record history list reflects a new submitted version dated 2026-04-17 with updates labeled for Contacts/Locations and Study Status, and it also shows an interface revision update to v3.5.3. An earlier revision reference (v3.5.2) is removed from the comparison list.SummaryDifference0.4%

- Check27 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the history.SummaryDifference0.1%

- Check56 days agoChange DetectedVersion 35, submitted on 2026-03-16, adds updates to Study Status and Contacts/Locations and updates the record revision to v3.5.0.SummaryDifference0.4%

- Check63 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check85 days agoChange DetectedVersion 34 updates the record by renaming the study to include Placebo With ADT and adding the Contacts/Locations, Study Design, Study Status, and Study Identification sections. These changes align the study's identification with the protocol and provide essential administrative details for tracking.SummaryDifference0.5%

- Check92 days agoChange DetectedAdded Revision: v3.4.2 to the history. Removed the government funding lapse notice and operating-status guidance that previously appeared on the page.SummaryDifference0.5%

Stay in the know with updates to Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page.